[CRISPR as a functional cure for hemoglobinopathies].

Area of Science:

• Hematology
• Gene Therapy
• Genetics

Background:

• Severe hemoglobinopathies like sickle cell disease and beta-thalassemia pose significant global health challenges.
• Current gene therapy strategies aim for a functional cure by enhancing fetal hemoglobin (HbF) production.
• CRISPR-Cas9 technology allows precise genetic modification of hematopoietic stem cells.

Purpose of the Study:

• To review the current state and future prospects of CRISPR-based gene editing for severe hemoglobinopathies.
• To evaluate the accessibility and scalability of existing ex vivo therapeutic approaches.
• To explore the potential of in vivo gene editing for broader treatment access.

Main Methods:

• Review of existing literature on CRISPR gene editing for sickle cell disease and beta-thalassemia.
• Analysis of current ex vivo therapeutic protocols and their resource requirements.
• Assessment of emerging in vivo gene editing strategies and their feasibility.

Main Results:

• Ex vivo CRISPR gene editing shows promise for treating severe hemoglobinopathies by increasing HbF levels.
• Current ex vivo approaches necessitate specialized facilities and significant resources, hindering widespread accessibility.
• In vivo gene editing approaches are under development and hold potential for improved global access.

Conclusions:

• CRISPR-based therapies represent a promising avenue for functional cures of severe hemoglobinopathies.
• The accessibility of current ex vivo treatments is a major limitation, particularly in resource-limited settings.
• Development of in vivo gene editing methods is crucial for achieving scalable, affordable, and globally accessible treatments for these diseases.